Acute Myeloblastic Leukemia with Maturation

Search Trials
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status:
Completed
Last Changed:
Oct 5, 2018
First Changed:
Jan 23, 2007
Disease(s):
Leukemia
Intervention(s):
sargramostimbexarotenecytogenetic analysisfluorescence in situ hybridizationflow cytometrylaboratory biomarker analysisbiopsy
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Status:
Completed
Last Changed:
Mar 10, 2010
First Changed:
Feb 12, 2004
Disease(s):
Leukemia
Intervention(s):
fludarabine phosphatetriapine
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
Status:
Completed
Last Changed:
Sep 30, 2015
First Changed:
Jun 16, 2004
Disease(s):
Leukemia
Intervention(s):
gemtuzumab ozogamicinobservationCytosine arabinosideDaunomycin
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status:
Terminated
Last Changed:
Dec 28, 2017
First Changed:
Jan 8, 2009
Disease(s):
Leukemia
Intervention(s):
bortezomibvorinostat
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Status:
Unknown status
Last Changed:
Jul 24, 2012
First Changed:
Sep 9, 2004
Disease(s):
Leukemia
Intervention(s):
gemtuzumab ozogamicin

Connect. Empower. Inspire.